Cost-effectiveness analysis of irinotecan plus fluorouracil/folinic acid compared with fluorouracil/folinic acid alone as first-line treatment for advanced colorectal cancer

Wingo PA, Tons T, Bolden S, et al. Cancer statistic, 1995. CA Cancer J Clin 1995;45:8–30.

Cáncer en España. Madrid: Ministerio de Sanidad y Consumo, 1993.

Regidor E, Rodríguez C, Gutierrez F, et al. Indicadores de salud. Tercera evaluación en España del programa regional europeo. Salud paratodos. Madrid: Ministerio de Sanidad y Consumo, 1995.

Cancer incidence in five continnents. Vol IV, V, VI, y VII (1982, 1987, 1992, 1995 y 1997). IARC Scientifics publications, No 42, 88,107,120,132.

Pommier Y, Tanizawa A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. En: Liu LF, editor. Advances in Pharmacology. New York: Academic Press, 1994;29B:73–92.

Midgley R, Kerr D. Colorectal cancer. Lancet 1999;353: 391–9.

Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–8.

Rougier P, Van Custem E, Bajetta E, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407–12.

Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil campared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–7.

Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905–14.

Consejo general de colegios oficiales de farmacéuticos de España. Catalogue of Pharmaceutical Specialties, Madrid: 2001.

Gisbert R, Brosa M. Base de datos de costes sanitarios. Versión 1.1c. Barcelona: Soikos, 2001.

Cunningham D, Falk S, Jackson DL. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer 2002;86:1677–83.

Montero MC, Valdivia ML, Carvajal E, et al. Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm Worls Sci 1994;16(4):187–92.

Schmitt C, Levy-Piedbois C, Frappé M, et al. Cost-effectiveness analysis of irinotecan+5FU/FA as first-line therapy in advanced colorectal cancer. Annals of Oncology 2000: 11(Suppl. 4):47.

Plans-Rubió P. Cost-effectiveness of pharmacologic treatments for the reduction of blood lipids. Med Clin (Barc) 1995;105:327–33.

Plans-Rubió P. Cost-effectiveness of cardiovascular prevention programs in Spain. Int J Technol Assess Health Care 1998;14:320–30.